MSI-H tumors exhibit a high mutation burden, leading to the production of neoantigens that can be recognized by the immune system. This makes MSI-H tumors more likely to respond to immunotherapy, particularly immune checkpoint inhibitors like pembrolizumab and nivolumab. These drugs block proteins that prevent T-cells from attacking cancer cells, thus enhancing the body's immune response against the tumor.
